Other languages Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.06 ^USD	-4.50%		+6.00%	+0.95%

Apr. 01	Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 26	Transcript : Quince Therapeutics, Inc. - Special Call

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01
Quince Therapeutics, Inc. Launches Scientific Advisory Board	Feb. 22
Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors	Feb. 15
Quince Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer	23-10-26
Quince Therapeutics, Inc. Appoints Luca Benatti as Director	23-10-23
Quince Therapeutics, Inc. acquired EryDel S.p.A	23-10-22
Quince Says US FDA Lifts Partial Clinical Hold on EryDel's Treatment for Ataxia-Telangiectasia	23-09-28
Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug Application for Its Lead Phase 3 Asset, Erydex	23-09-28
Quince Therapeutics Appoints Charles S. Ryan as President	23-09-06
Insider Buy: Quince Therapeutics	23-08-11
Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023	23-08-10
Quince Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Quince Therapeutics rileva EryDel SpA e il suo asset di fase 3 mirato all'atassia-telangectasia, per cui attualmente non esistono trattamenti approvati, con opportunità stimate per un picco di vendite di oltre 1 miliardo di dollari USA	23-07-24
Sector Update: Health Care Stocks Declining Late Monday	23-07-24
Sector Update: Health Care Stocks Easing Monday Afternoon	23-07-24
Quince Therapeutics to Acquire EryDel in All-Stock Deal	23-07-24
Quince Therapeutics, Inc. Announces Board and Executive Changes	23-07-24
Quince Therapeutics Shares Rise Pre-Bell After Echo Lake Capital Raises Acquisition Offer	23-07-13
Quince Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Other languages

Filters